-
公开(公告)号：US11858994B2
公开(公告)日：2024-01-02
申请号：US16494228
申请日：2018-03-14
Inventor： Seiji Matsumoto , Ryuji Suzuki
IPC: C07K16/02 , G01N33/574 , G16B25/10 , C12Q1/6886 , G16H20/10 , G16H50/30 , C07K16/28 , A61K45/06
CPC classification number: C07K16/2809 , C07K16/2815 , G01N33/574 , G16B25/10 , G16H20/10 , G16H50/30 , A61K45/06 , C12Q1/6886 , C12Q2600/106 , G01N2800/52
Abstract: T cell receptor (TCR) diversity of a subject, including TCR diversity in CD8+ T cell subsets, is used as a predictive indicator of responsiveness of the subject to cancer immunotherapy prior to initiation of the immunotherapy. Exemplified immunotherapy comprises administering an immune checkpoint inhibitor to a subject, wherein a TCR diversity value in CD8+ T cell subsets from the subject, such as CD8+ T cell subpopulations defined by differential cell surface marker expression, is higher than a reference value.
-
公开(公告)号：US20200338135A1
公开(公告)日：2020-10-29
申请号：US16958962
申请日：2018-12-27
Inventor： Tomohiro MATSUYAMA , Takayuki NAKAGOMI , Yu FUKUDA
Abstract: A lipocalin-type prostaglandin D2 synthase (L-PGDS) production promoting agent, more specifically an L-PGDS production promoting agent in pericytes or ischemia-induced multipotent stem cells (iSCs) dedifferentiated from pericytes. A substance having an L-PGDS production promoting action is contained in an extract from inflamed tissues inoculated with vaccinia virus. An L-PGDS production promoting agent is highly useful as a prophylactic, therapeutic or relapse prophylactic agent for a disease in which the effect by promotion of L-PGDS expression is expected to be effective, including a cerebrovascular disorder such as cerebral infarction, dementia such as Alzheimer's disease, or a sleep disorder.
-
公开(公告)号：US20200268703A1
公开(公告)日：2020-08-27
申请号：US16495045
申请日：2018-03-20
Applicant: Takahito JOMORI , HYOGO COLLEGE OF MEDICINE
Inventor： Shojiro KIKUCHI , Mitsuru SASAKO , Hiroto MIWA , Hisashi SHINOHARA , Hiromitsu KISHIMOTO , Kazuma NOGUCHI , Takahito JOMORI
Abstract: The present invention relates to a medicine for treating a patient with advanced or recurrent cancer which is non-responsive or non-tolerant to standard chemotherapy and incurable and unresectable, the medicine comprising propagermanium.
-
公开(公告)号：US20150044691A1
公开(公告)日：2015-02-12
申请号：US14523658
申请日：2014-10-24
Applicant: Shimadzu Corporation , Educational Corporation Mukogawa Gakuin , Hyogo College of Medicine
Inventor： Eiichi Matsuo , Naoki Kaneko , Makoto Watanabe , Osamu Nishimura , Noboru Okamura , Akinobu Gotoh
IPC: G01N33/574
CPC classification number: G01N33/57438 , C12N9/96 , G01N33/6893 , G01N2333/4724 , G01N2333/988
Abstract: The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer.
Abstract translation: 本发明提供了用于肾癌的血液标志物，更具体地，可以实际用于肾癌的临床诊断的血液标志物。 本发明还提供了一种血液标志物，其可以实际用于治疗之后的后续，例如手术和治疗期间，例如用于肾癌的药物。 选自Galectin-1，Galectin-3和α-烯醇化酶的肾癌血液标志物。 Galectin-1和/或Galectin-3作为肾癌的血液标志物，用于在诊断成像之前进行的检查。 α-烯醇化酶作为用于肾癌治疗期间和/或治疗期间的肾癌的血液标志物。
-
公开(公告)号：US20130171660A1
公开(公告)日：2013-07-04
申请号：US13728932
申请日：2012-12-27
Applicant: SHIMADZU CORPORATION , EDUCATIONAL CORPORATION MUKOGAWA GAKUIN , HYOGO COLLEGE OF MEDICINE
Inventor： Eiichi Matsuo , Naoki Kaneko , Makoto Watanabe , Osamu Nishimura , Noboru Okamura , Akinobu Gotoh
CPC classification number: G01N33/57438 , C12N9/96 , G01N33/6893 , G01N2333/4724 , G01N2333/988
Abstract: The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer.
Abstract translation: 本发明提供了用于肾癌的血液标志物，更具体地，可以实际用于肾癌的临床诊断的血液标志物。 本发明还提供了一种血液标志物，其可以实际用于治疗之后的后续，例如手术和治疗期间，例如用于肾癌的药物。 选自Galectin-1，Galectin-3和α-烯醇化酶的肾癌的血液标志物。 Galectin-1和/或Galectin-3作为肾癌的血液标志物，用于在诊断成像之前进行的检查。 α-烯醇化酶作为用于肾癌治疗期间和/或之后的监测用于肾癌的血液标志物。
-
Patent Agency Ranking
公开(公告)号：US20220372130A1
公开(公告)日：2022-11-24
申请号：US17813016
申请日：2022-07-15
Inventor： Tomohiro YOSHIMOTO , Joseph M. PALUMBO , Violetta I. STONE , Toru KATO , Koubun YASUDA
IPC: C07K16/24 , A61K39/395
Abstract: Based on the identification of IL-33 as an exacerbating factor in endometriosis and adenomyosis uteri, a method for treating or alleviating endometriosis or adenomyosis uteri, involves administering an IL-33 antagonist, which is capable of inhibiting the function of IL-33. The IL-33 antagonist is useful for treating, preventing or alleviating endometriosis and uterine adenomyosis uteri.
-
公开(公告)号：US20190209073A1
公开(公告)日：2019-07-11
申请号：US16299405
申请日：2019-03-12
Applicant: OSAKA PREFECTURE UNIVERSITY PUBLIC CORPORATION , EuSense Medical Co., Ltd. , HYOGO COLLEGE OF MEDICINE , J craft Co., Ltd.
Inventor： Michifumi Yoshioka , Katsufumi Inoue , Yoshitaka Oku
CPC classification number: A61B5/4205 , A61B5/08 , A61B5/0816 , A61B5/11 , A61B5/7257 , A61B5/7275 , A61B10/00 , G06N20/10
Abstract: A swallowing diagnosis apparatus includes a controller which enables a first swallowing determination process of determining whether or not there is an aspiration risk in the swallowing on the basis of respiratory phases before and after a period in which swallowing has been estimated as having occurred; and a second swallowing determination process of extracting reference information including at least one of the sound information and the respiration information in a predetermined period including the period in which swallowing has been estimated as having occurred, obtaining a feature quantity from the extracted reference information, and performing a machine learning process on the obtained feature quantity to determine whether or not there is a possibility of dysphagia in the swallowing; and a display control process of causing a determination result obtained by the first swallowing determination process and a determination result obtained by the second swallowing determination process to be displayed.
-
公开(公告)号：US20160057978A1
公开(公告)日：2016-03-03
申请号：US14888398
申请日：2014-04-30
Applicant: HYOGO COLLEGE OF MEDICINE , MIE UNIVERSITY
Inventor： Kiyofumi YAMANISHI , Hitoshi MIZUTANI , Yasutomo IMAI , Tomohiro YOSHIMOTO , Kenji NAKANISHI
IPC: A01K67/027 , A61K49/00
CPC classification number: A01K67/0278 , A01K67/0275 , A01K2217/052 , A01K2217/206 , A01K2227/105 , A01K2267/035 , A01K2267/0368 , A61K49/0008 , C07K14/54
Abstract: The present invention provides a transgenic non-human mammal retaining, in a specifically expressible state, a DNA encoding IL-33 in the skin, and having one or more features selected from the group consisting of (1) spontaneous onset of dermatitis, (2) increase in the number of inflammatory cells, (3) increase in total IgE concentration, histamine concentration, cytokine concentration and/or chemokine concentration, and (4) increase in scratching time, under SPF (specific pathogen free) breeding conditions, as compared to a corresponding non-transgenic non-human mammal, and the like.
Abstract translation: 本发明提供了一种转基因非人哺乳动物，其在特定可表达状态下保留编码皮肤中的IL-33的DNA，并且具有选自（1）自发性皮炎，（2） ）炎症细胞数量增加，（3）总IgE浓度增加，组胺浓度，细胞因子浓度和/或趋化因子浓度增加，（4）在SPF（无特定病原体）培养条件下，划痕时间增加， 相应的非转基因非人哺乳动物等。
-
公开(公告)号：US09212169B2
公开(公告)日：2015-12-15
申请号：US14382048
申请日：2013-03-01
Applicant: HYOGO COLLEGE OF MEDICINE , KAGOSHIMA UNIVERSITY , OSAKA UNIVERSITY
Inventor： Kazutake Tsujikawa , Akito Tanaka , Shunji Aoki , Hiroaki Mizuno , Miyuki Tokoro , Tatsuhiko Furukawa
IPC: C07D403/04
CPC classification number: C07D403/04
Abstract: The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof.
Abstract translation: 本发明的目的在于提供能够抑制作为各种疾病的新型治疗方法的靶标的PCA-1的化合物和该化合物的药物用途。 由式（I）表示的化合物或其药学上可接受的盐，其中每个符号如说明书中所定义。
-
公开(公告)号：US20240052345A1
公开(公告)日：2024-02-15
申请号：US18258991
申请日：2021-12-22
Applicant: RIKEN , HYOGO COLLEGE OF MEDICINE
Inventor： Haruhisa INOUE , Mika SUGA , Takayuki KONDO , Takashi KIMURA
IPC: C12N15/113 , A61P21/00
CPC classification number: C12N15/113 , A61P21/00 , C12N2310/11 , C12N2310/321 , C12N2310/3231 , C12N2310/313 , C12N2310/315
Abstract: The present invention provides novel antisense oligonucleotide pharmaceutical compositions having higher RNA aggregate-removing activity than conventional pharmaceutical compositions. The pharmaceutical composition of the present invention contains an oligonucleotide having any base sequence of a repeated sequence in which cytosine-adenine-guanine trinucleotides are repeated 5 to 13 times, from the 5′ end to the 3′ end, and the oligonucleotide has a mixmer structure containing at least two types of RNase H inactive nucleotide analogs. The present invention provides the pharmaceutical composition of the present invention used for the treatment of some symptoms of myotonic dystrophy type 1 disease.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.021 seconds)
